MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma

BACKGROUND: This study aimed to better understand the prognostic effect of multiple genetic markers and identify more subpopulations at ultra high risk of poor outcome in bone marrow (BM) metastatic neuroblastoma (NB). METHODS: We screened the MYCN, 1p36 and 11q23 loss of heterozygosity (LOH) status...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Zhi‐Xia, Xing, Tian‐Yu, Zhao, Wen, Zhao, Qian, Wang, Xi‐Si, Su, Yan, Gao, Chao, Liu, Shu‐Guang, Ma, Xiao‐Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041068/
https://www.ncbi.nlm.nih.gov/pubmed/35137546
http://dx.doi.org/10.1002/cam4.4583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041068/
https://www.ncbi.nlm.nih.gov/pubmed/35137546
http://dx.doi.org/10.1002/cam4.4583

Ejemplares similares